American Heart Journal
Volume 158, Issue 4 , Pages e51-e57 , October 2009

Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study

  • Ralf Köster, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Ralf Köster, MD, University Heart Center, Clinic for Cardiology and Angiology Martinistrasse 52, 20246 Hamburg.
    • ,
  • Jan Kaehler, MD
    • ,
  • Thomas Meinertz, MD
    • ,
  • for the REDUCTION Study Group

Received 16 March 2009 ,Accepted 5 June 2009.

  • Image Result

    Heart rate reduction by ivabradine over a period of 4 months. Average dosage was 9 mg started at baseline, 10.2 mg at first month, and 10.5 mg after 4 months. The baseline value displayed represents h

    Heart rate reduction by ivabradine over a period of 4 months. Average dosage was 9 mg started at baseline, 10.2 mg at first month, and 10.5 mg after 4 months. The baseline value displayed represents heart rate before start of ivabradine therapy.

  • Image Result
    Number of angina pectoris attacks at baseline and at follow-up. Ivabradine significantly reduced the number of angina pectoris attacks registered in the week before the visit.

    Number of angina pectoris attacks at baseline and at follow-up. Ivabradine significantly reduced the number of angina pectoris attacks registered in the week before the visit.

  • Image Result
    Nitrate consumption at baseline and at follow-up. Total number of nitrate spray and capsule use during the week before evaluation was significantly reduced by ivabradine.

    Nitrate consumption at baseline and at follow-up. Total number of nitrate spray and capsule use during the week before evaluation was significantly reduced by ivabradine.

PII: S0002-8703(09)00450-5

doi: 10.1016/j.ahj.2009.06.008

American Heart Journal
Volume 158, Issue 4 , Pages e51-e57 , October 2009

Article Tools

* Image Usage & Resolution